海正藥業(600267.SH)擬43.37億-44.84億元收購瀚暉製藥49%股權 明起復牌
格隆匯 7 月 20日丨海正藥業(600267.SH)公佈,公司擬向HPPC發行股份、可轉換公司債券及支付現金購買其持有的瀚暉製藥有限公司49%股權。
經初步預估,瀚暉製藥100%股權的預估值初步確定為88.50億元至91.50億元之間,經交易雙方協商一致,標的資產(即標的公司49%股權)的預估交易價格區間暫定為人民幣43.37億元至44.84億元。最終交易價格將以具有證券、期貨相關業務資格的資產評估機構出具並經國有資產監督管理部門備案的資產評估報告所確定的評估值為依據,由交易相關各方協商確定。
其中,公司擬以現金方式支付的交易價格為15億元,剩餘交易價格(即標的資產交易對價減去上市公司以現金方式向HPPC支付的交易對價15億元)的65%由上市公司以發行股份的方式支付,剩餘交易價格的35%由上市公司以發行可轉換公司債券的方式支付。
同時,公司擬向椒江國資公司、員工持股計劃發行股份及可轉換公司債券募集配套資金不超過15億元,不超過此次交易中以發行股份及可轉換公司債券方式購買資產的交易價格的100%。此次發行股份募集配套資金金額不超過7億元,發行可轉換公司債券募集配套資金金額不超過8億元,其中椒江國資公司認購股份不超過7億元,員工持股計劃認購可轉換公司債券不超過8億元。
根據相關規定,經向上海證券交易所申請,公司股票將於2020年7月21日開市起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.